Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis
Efficacy, Safety and Pharmacokinetics of Ascending Dosages of Emodepside and in Comparison to Ivermectin Against Strongyloidiasis Stercoralis in Adults: Randomized Stage II Seamless Adaptive Controlled Trials
Sponsor: National Institute of Public Health, Vientiane, Laos
Listed as NCT06373835, this PHASE2 trial focuses on Strongyloides Stercoralis Infection and Strongyloidiasis and remains completed. Sponsored by National Institute of Public Health, Vientiane, Laos, it has been updated 6 times since 2024, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Dec 2024 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Public Health, Vientiane, Laos
- Swiss Tropical & Public Health Institute
For direct contact, visit the study record on ClinicalTrials.gov .